Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China

Background: As the first domestic PD-1 antibody approved for lung cancer in China, camrelizumab has exhibited proven effectiveness for non-small-cell lung cancer (NSCLC) patients. However, the cost-effectiveness of this new regimen remains to be investigated. Objective: To evaluate the cost-effectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Guiyuan, Gu, Lingna, Chen, Xuan, Wang, Fan, Chen, Bohua, Zhao, Jie, Lu, Yun, Chang, Feng, Zhu, Yumei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702426/
https://www.ncbi.nlm.nih.gov/pubmed/34957008
http://dx.doi.org/10.3389/fpubh.2021.743558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702426/
https://www.ncbi.nlm.nih.gov/pubmed/34957008
http://dx.doi.org/10.3389/fpubh.2021.743558

Ejemplares similares